Francisco Cordova, MD
Hospitalist · Rancho Mirage, CANPI 1124303144
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $686 and has fallen 57.2% since, to $293 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$387
- AstraZeneca$323
- Bayer$219
- Lilly USA, LLC$166
- Intuitive Surgical$145
- Conformis, Inc.$144
- plus $729 from 19 others
Across 3 payments — averaging $3083.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Shire North American Group Inc$2K
What the payments were for
- Food & beverage$2,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $387 |
| AstraZeneca | 8 | $323 |
| Bayer | 7 | $219 |
| Lilly USA, LLC | 7 | $166 |
| Intuitive Surgical | 1 | $145 |
| Conformis, Inc. | 1 | $144 |
| Sanofi | 1 | $114 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| AbbVie | 3 | $64 |
| Boston Scientific | 3 | $56 |
| Pfizer | 2 | $47 |
| GSK | 3 | $47 |
| Novo Nordisk | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Viatris Specialty LLC | 2 | $36 |
| Shield Therapeutics Inc | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Qiagen, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Biocryst US Sales Co., LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$145
- iTotal Identity PS$144
- Identity Imprint Knee Replacement System$144
- Kerendia$129
- Repatha$122
- FARXIGA$117
- Enhertu$115
How this compares
$2,113 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $64,037 |
| JardianceEmpagliflozin | 62 | $59,759 |
| MounjaroTirzepatide | 38 | $48,798 |
| OzempicSemaglutide | 27 | $33,611 |
| FarxigaDapagliflozin Propanediol | 22 | $19,519 |
| XareltoRivaroxaban | 15 | $18,325 |
| MyrbetriqMirabegron | 24 | $16,614 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,653 |
| Atorvastatin Calcium | 434 | $3,954 |
| Levothyroxine Sodium | 300 | $3,792 |
| Rosuvastatin Calcium | 192 | $3,548 |
| Losartan Potassium | 224 | $2,504 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,451 |
| Amlodipine Besylate | 266 | $2,219 |
| Tamsulosin Hcl | 149 | $2,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $64,03753 claims |
| Boehringer IngelheimJardiance | $17 | $59,75962 claims |
| Lilly USA, LLCMounjaro | $166 | $48,79838 claims |
| Novo NordiskOzempic | $37 | $33,61127 claims |
| AstraZenecaFarxiga | $323 | $19,51922 claims |
| Johnson & JohnsonXarelto | $20 | $18,32515 claims |
| GSKAnoro Ellipta | $47 | $7,65311 claims |
| AbbVieSynthroid | $64 | $1,23024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Rancho Mirage
- Amar ShahRancho Mirage$4K
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.